在静脉血栓栓塞症后扩展抗凝药
Rasmus Laursen1, Hanne M Søndergaard1, Pia Børding1
1Department of Cardiology, Regional Hospital Viborg, Denmark.
Danish medical journal
|September 26, 2024
概括
延长抗凝药对于静脉血栓栓塞 (VTE) 患者来说是常见的,特别是那些高风险或中等风险患者. 在这个现实世界的诊所里,大多数患者都接受了长期治疗,非维生素K对抗剂口服抗凝剂是首选选择.
科学领域:
- 医学 医学 医学 医学 医学
- 心脏病学 心脏病学
- 血液学 血液学 血液学
背景情况:
- 静脉血栓栓塞 (VTE) 复发风险因指数事件而异.
- 推扩展抗凝剂治疗高风险患者,并考虑中等风险静脉瘤患者.
- 在VTE扩展抗凝治疗的临床实践需要进一步的洞察.
研究的目的:
- 调查延长VTE患者抗凝血治疗的临床实践.
- 根据复发风险,分析延长抗凝药的决策过程.
主要方法:
- 从2020年1月到2021年6月对VTE患者的回顾性研究.
- 患者分为低 (<3%),中等 (3-8%) 和高 (>8%) 复发风险组.
- 在一个多学科的VTE诊所中做出的治疗决定.
主要成果:
- 分析了315名VTE患者,58.7%的患者有中等复发风险.
- 所有符合条件的患者中有80.3%接受了延长抗凝治疗.
- 延长治疗的使用率为高风险患者的97.9%,中等风险患者的82.7%,低风险患者的15.2%.
- 非维生素K对抗剂口服抗凝剂 (82.2%) 是延长治疗的首选.
结论:
- 在这家诊所的大多数VTE患者过渡到扩展抗凝药.
- 在不同风险类别中广泛采用扩展治疗.
- 需要进一步研究患者和医生的偏好如何影响治疗决策.
相关概念视频
Venous Thrombosis III: Interprofessional Care
3
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
3
Venous Thrombosis IV: Nursing Management
3
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
3
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Venous Thrombosis I: Introduction
3
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
3
Anticoagulant Drugs: Low-Molecular-Weight Heparins
649
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
649
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
3
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
3


